SIRIUS XM HOLDINGS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SIRIUS XM HOLDINGS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.40B | Jan 31, 2018 |
| FY2017 | Sep 30, 2017 | $1.38B | Jan 31, 2018 |
| FY2017 | Jun 30, 2017 | $1.35B | Jan 31, 2018 |
| FY2017 | Mar 31, 2017 | $1.29B | Jan 31, 2018 |
| FY2017 | Dec 31, 2016 | $1.30B | Jan 31, 2018 |
| FY2017 | Sep 30, 2016 | $1.28B | Jan 31, 2018 |
| FY2017 | Jun 30, 2016 | $1.24B | Jan 31, 2018 |
| FY2017 | Mar 31, 2016 | $1.20B | Jan 31, 2018 |
| FY2016 | Dec 31, 2015 | $1.20B | Feb 2, 2017 |
| FY2016 | Sep 30, 2015 | $1.17B | Feb 2, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.56B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $8.70B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $8.95B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $9.00B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $8.70B | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | $2.19B | Feb 2, 2021 |
| FY2020 | Sep 30, 2020 | $2.03B | Feb 2, 2021 |
| FY2020 | Jun 30, 2020 | $1.87B | Feb 2, 2021 |
| FY2020 | Mar 31, 2020 | $1.95B | Feb 2, 2021 |
| FY2020 | Dec 31, 2019 | $2.06B | Feb 2, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $1.09B | Feb 5, 2015 |
| FY2014 | Sep 30, 2014 | $1.06B | Feb 5, 2015 |
| FY2014 | Jun 30, 2014 | $1.04B | Feb 5, 2015 |
| FY2014 | Mar 31, 2014 | $997.71M | Feb 5, 2015 |
| FY2014 | Dec 31, 2013 | $1.00B | Feb 5, 2015 |
| FY2014 | Sep 30, 2013 | $961.51M | Feb 5, 2015 |
| FY2014 | Jun 30, 2013 | $940.11M | Feb 5, 2015 |
| FY2014 | Mar 31, 2013 | $897.40M | Feb 5, 2015 |
| FY2013 | Dec 31, 2012 | $892.42M | Feb 4, 2014 |
| FY2013 | Sep 30, 2012 | $867.36M | Feb 4, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.49B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.62B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $4.79B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $4.92B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $4.77B | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $4.51B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $4.41B | Feb 1, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $805.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($1.67B) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $786.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $908.00M | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $1.31B | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | ($677.00M) | Feb 2, 2021 |
| FY2020 | Sep 30, 2020 | $272.00M | Feb 2, 2021 |
| FY2020 | Jun 30, 2020 | $243.00M | Feb 2, 2021 |
| FY2020 | Mar 31, 2020 | $293.00M | Feb 2, 2021 |
| FY2020 | Dec 31, 2019 | $243.00M | Feb 2, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($1.52B) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $1.81B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.92B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $2.02B | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | ($503.00M) | Feb 2, 2021 |
| FY2020 | Sep 30, 2020 | $478.00M | Feb 2, 2021 |
| FY2020 | Jun 30, 2020 | $415.00M | Feb 2, 2021 |
| FY2020 | Mar 31, 2020 | $468.00M | Feb 2, 2021 |
| FY2020 | Dec 31, 2019 | $399.00M | Feb 2, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $296.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $322.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $285.00M | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $265.00M | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $263.00M | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $280.00M | Feb 1, 2022 |
| FY2020 | Dec 31, 2018 | $123.00M | Feb 2, 2021 |
| FY2019 | Dec 31, 2017 | $112.00M | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $82.15M | Jan 30, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.74B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $1.83B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.98B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $2.00B | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $2.02B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $2.02B | Feb 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.88B | Feb 2, 2021 |
| FY2019 | Dec 31, 2017 | $1.86B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $1.72B | Jan 30, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $653.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $728.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $650.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $426.00M | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $388.00M | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $350.00M | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $363.00M | Feb 1, 2022 |
| FY2020 | Dec 31, 2018 | $355.00M | Feb 2, 2021 |
| FY2019 | Dec 31, 2017 | $288.00M | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $205.83M | Jan 30, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.24B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $27.52B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $30.06B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $10.02B | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.27B | Feb 2, 2023 |
| FY2021 | Dec 31, 2020 | $10.33B | Feb 1, 2022 |
| FY2020 | Dec 31, 2019 | $11.15B | Feb 2, 2021 |
| FY2019 | Dec 31, 2018 | $8.17B | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | $8.33B | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | $8.00B | Jan 31, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.67B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $16.45B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $16.95B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $13.37B | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $12.90B | Feb 2, 2023 |
| FY2021 | Dec 31, 2020 | $12.62B | Feb 1, 2022 |
| FY2020 | Dec 31, 2019 | $11.89B | Feb 2, 2021 |
| FY2019 | Dec 31, 2018 | $9.99B | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | $9.85B | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | $8.80B | Jan 31, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.56B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $11.07B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $10.08B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | ($3.35B) | Feb 1, 2024 |
| FY2023 | Dec 31, 2021 | ($2.63B) | Feb 1, 2024 |
| FY2023 | Dec 31, 2020 | ($2.29B) | Feb 1, 2024 |
| FY2022 | Dec 31, 2019 | ($736.00M) | Feb 2, 2023 |
| FY2021 | Dec 31, 2018 | ($1.82B) | Feb 1, 2022 |
| FY2020 | Dec 31, 2017 | ($1.52B) | Feb 2, 2021 |
| FY2019 | Dec 31, 2016 | ($792.00M) | Feb 4, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.39B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $12.39B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $15.21B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $15.21B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $3.15B | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $3.12B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $3.84B | Feb 1, 2022 |
| FY2020 | Dec 31, 2018 | $2.29B | Feb 2, 2021 |
| FY2019 | Dec 31, 2017 | $2.29B | Feb 4, 2020 |
| FY2017 | Dec 31, 2016 | $2.21B | Jan 31, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.61B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $11.12B | Feb 5, 2026 |
| FY2024 | Jan 1, 2024 | $15.35B | Jan 30, 2025 |
| FY2024 | Dec 31, 2023 | $15.35B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | ($3.35B) | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.64B) | Feb 2, 2023 |
| FY2021 | Dec 31, 2020 | ($2.29B) | Feb 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.14B) | Feb 2, 2021 |
| FY2019 | Dec 31, 2018 | ($2.06B) | Feb 4, 2020 |
| FY2018 | Jan 1, 2018 | ($3.23B) | Jan 30, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $162.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $306.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $362.00M | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $191.00M | Feb 1, 2024 |
| FY2023 | Dec 31, 2020 | $71.00M | Feb 1, 2024 |
| FY2022 | Dec 31, 2019 | $106.00M | Feb 2, 2023 |
| FY2021 | Dec 31, 2018 | $54.00M | Feb 1, 2022 |
| FY2020 | Dec 31, 2017 | $69.00M | Feb 2, 2021 |
| FY2019 | Dec 31, 2016 | $214.00M | Feb 4, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $3.01B | Feb 9, 2012 |
| FY2011 | Dec 31, 2010 | $3.22B | Feb 9, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 2, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 2, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 2, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 335.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 339.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | 3.89B | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | 3.97B | Feb 2, 2023 |
| FY2021 | Dec 31, 2020 | 4.17B | Feb 1, 2022 |
| FY2020 | Dec 31, 2019 | 4.41B | Feb 2, 2021 |
| FY2019 | Dec 31, 2018 | 4.35B | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | 4.53B | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | 4.74B | Jan 31, 2018 |